ENDOPHASE
Peptides / Glutathione / Aggregation Risk
Aggregation Risk

Aggregation Risk for Glutathione

Before a peptide becomes a purchase order, it pays to look hard at the sequence itself. EndoPhase gives you a read on the hydrophobic runs and motifs that tend to drive aggregation, for Glutathione and any sequence you are weighing up.

Run Glutathione preflight

Before a peptide becomes a purchase order, it pays to look hard at the sequence itself. For a candidate like Glutathione, the questions worth answering early are practical: is the sequence clean to make, is it stable, and does the intended route even make sense. aggregation risk is the part of that picture EndoPhase focuses on here.

What aggregation risk looks at

For Glutathione, EndoPhase surfaces a read on the hydrophobic runs and motifs that tend to drive aggregation, in plain language, with the reasoning kept beside the result so a reviewer can agree or push back.

Why do this before synthesis

Most wasted peptide budget is decided at the sequence stage, long before the lab gets involved. The whole idea is to spend judgement before spending budget. The point is simple: decide what is worth making before you make it.

Request beta access

EndoPhase is research-use software. It does not sell peptides, give medical advice, diagnose, treat, or make claims about the safety or efficacy of any compound named here. Names are used as analysis subjects only.